International Journal of High Risk Behaviors and Addiction

Published by: Kowsar

Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran

Hossein Norouzian 1 , Mohammadreza Gholami 1 , Pegah Shakib 1 , Gholamreza Goudarzi 1 , * , Hamze Ghobadian Diali 2 and Azam Rezvani 3
Authors Information
1 Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, IR Iran
2 Razi Vaccine Serum Research Institute, Virology Department, Karaj, IR Iran
3 Deputy of Health Services, Lorestan University of Medical Sciences, Khorramabad, IR Iran
Article information
  • International Journal of High Risk Behaviors and Addiction: March 01, 2016, 5 (1); e25028
  • Published Online: January 18, 2016
  • Article Type: Research Article
  • Received: November 15, 2014
  • Revised: March 1, 2015
  • Accepted: March 9, 2015
  • DOI: 10.5812/ijhrba.25028

To Cite: Norouzian H, Gholami M, Shakib P, Goudarzi G, Ghobadian Diali H, et al. Prevalence of HCV Infections and Co-Infection With HBV and HIV and Associated Risk Factors Among Addicts in Drug Treatment Centers, Lorestan Province, Iran, Int J High Risk Behav Addict. 2016 ;5(1):e25028. doi: 10.5812/ijhrba.25028.

Abstract
Copyright © 2016, Zahedan University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Wild CP, Hall AJ. Primary prevention of hepatocellular carcinoma in developing countries. Mutat Res. 2000; 462(2-3): 381-93[PubMed]
  • 2. Burattini M, Massad E, Rozman M, Azevedo R, Carvalho H. Correlation between HIV and HCV in Brazilian prisoners: evidence for parenteral transmission inside prison. Rev Saude Publica. 2000; 34(5): 431-6[PubMed]
  • 3. Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005; 58(1): 96-107[DOI][PubMed]
  • 4. Zeldis JB, Jain S, Kuramoto IK, Richards C, Sazama K, Samuels S, et al. Seroepidemiology of viral infections among intravenous drug users in northern California. West J Med. 1992; 156(1): 30-5[PubMed]
  • 5. Mohammad Alizadeh AH, Alavian SM, Jafari K, Yazdi N. Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran. World J Gastroenterol. 2005; 11(26): 4085-9[PubMed]
  • 6. Alavian SM, Gholami B, Masarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. J Gastroenterol Hepatol. 2002; 17(10): 1092-7[PubMed]
  • 7. Hajiani E, Hashemi J, Masjedizadeh R, Shayesteh AA, Idani E, Rajabi T. Seroepidemiology of hepatitis C and its risk factors in Khuzestan Province, south-west of Iran: a case-control study. World J Gastroenterol. 2006; 12(30): 4884-7[PubMed]
  • 8. Taylor A, Goldberg D, Hutchinson S, Cameron S, Fox R. High risk injecting behaviour among injectors from Glasgow: cross sectional community wide surveys 1990-1999. J Epidemiol Community Health. 2001; 55(10): 766-7[PubMed]
  • 9. Zali MR, Aghazadeh R, Nowroozi A, Amir-Rasouly H. Anti-HCV antibody among Iranian IV drug users: is it a serious problem. Arch Iran Med. 2001; 4(3): 115-9
  • 10. Shafer KP, Hahn JA, Lum PJ, Ochoa K, Graves A, Moss A. Prevalence and correlates of HIV infection among young injection drug users in San Francisco. J Acquir Immune Defic Syndr. 2002; 31(4): 422-31[PubMed]
  • 11. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Iranian Med. 2005; 8(2): 84-90
  • 12. Samuel MC, Doherty PM, Bulterys M, Jenison SA. Association between heroin use, needle sharing and tattoos received in prison with hepatitis B and C positivity among street-recruited injecting drug users in New Mexico, USA. Epidemiol Infect. 2001; 127(3): 475-84[PubMed]
  • 13. Khani M, Vakili MM. Prevalence and risk factors of HIV, hepatitis B virus and hepatitis C virus infections in drug addicts among Zanjan prisoners. Arch Iranian Med. 2003; 6(1): 1-4
  • 14. Babudieri S, Longo B, Sarmati L, Starnini G, Dori L, Suligoi B, et al. Correlates of HIV, HBV, and HCV infections in a prison inmate population: results from a multicentre study in Italy. J Med Virol. 2005; 76(3): 311-7[DOI][PubMed]
  • 15. Rahbar A, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy. 2004; 15(2): 151-5[DOI]
  • 16. Kheirandish P, SeyedAlinaghi S, Jahani M, Shirzad H, Seyed Ahmadian M, Majidi A, et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health. 2009; 86(6): 902-8[DOI][PubMed]
  • 17. Mohtasham Amiri Z, Rezvani M, Jafari Shakib R, Jafari Shakib A. Prevalence of hepatitis C virus infection and risk factors of drug using prisoners in Guilan province. East Mediterr Health J. 2007; 13(2): 250-6[PubMed]
  • 18. Davoodian P, Dadvand H, Mahoori K, Amoozandeh A, Salavati A. Prevalence of selected sexually and blood-borne infections in Injecting drug abuser inmates of bandar abbas and roodan correction facilities, Iran, 2002. Braz J Infect Dis. 2009; 13(5): 356-8[DOI][PubMed]
  • 19. Alavi SM, Etemadi A. HIV/HBV, HIV/HCV and HIV/HTLV-1 co infection among injecting drug user patients hospitalized at the infectious disease ward of a training hospital in Iran. Pakistan Journal of Medical Sciences. 2007; 23(4): 510
  • 20. Evans JL, Hahn JA, Page-Shafer K, Lum PJ, Stein ES, Davidson PJ, et al. Gender differences in sexual and injection risk behavior among active young injection drug users in San Francisco (the UFO Study). J Urban Health. 2003; 80(1): 137-46[DOI][PubMed]
  • 21. Alavian SM, Kabir A, Ahmadi AB, Lankarani KB, Shahbabaie MA, Ahmadzad-Asl M. Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodial Int. 2010; 14(3): 253-62[DOI][PubMed]
  • 22. Kafi-abad SA, Rezvan H, Abolghasemi H, Talebian A. Prevalence and trends of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among blood donors in Iran, 2004 through 2007. Transfusion. 2009; 49(10): 2214-20[DOI][PubMed]
  • 23. Van Staa A, Hardon A. Injection practices in the developing world. Geneva; World Health Organization. 1996;
  • 24. Mele A, Tosti ME, Marzolini A, Moiraghi A, Ragni P, Gallo G, et al. Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group. J Viral Hepat. 2000; 7(1): 30-5[PubMed]
  • 25. Akbari A, Imanieh MH, Karimi M, Tabatabaee HR. Hepatitis C virus antibody positive cases in multitransfused thalassemic patients in South of Iran. Hepat Mon. 2007; 7(2): 63-6
  • 26. Alavian SM, Fallahian F, Lankarani KB. Comparison of seroepidemiology and transmission modes of viral hepatitis C in Iran and Pakistan. Hepat Mon. 2008; 8(1): 51-9
  • 27. Aceijas C, Friedman SR, Cooper HL, Wiessing L, Stimson GV, Hickman M. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect. 2006; 82 Suppl 3-7[DOI][PubMed]
  • 28. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J. 2006; 3: 12[DOI][PubMed]
  • 29. Quaglio G, Lugoboni F, Pajusco B, Sarti M, Talamini G, Lechi A, et al. Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. Clin Infect Dis. 2003; 37(1): 33-40[DOI][PubMed]
  • 30. Day C, Nassirimanesh B, Shakeshaft A, Dolan K. Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduct J. 2006; 3: 2[DOI][PubMed]
  • 31. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect. 2004; 132(3): 409-15[PubMed]
  • 32. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007; 18(5): 359-63[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments